Endogenous opioid peptide-mediated neurotransmission in central and pericentral nuclei of the inferior colliculus recruits mu(1)-opioid receptor to modulate post-ictal antinociception

Background: The aim of the present work was to investigate the involvement of the mu(1)-endogenous opioid peptide receptor-mediated system in post-ictal antinociception. Methods: Antinociceptive responses were determined by the tail-flick test after pre-treatment with the selective mu(1)-opioid receptor antagonist naloxonazine, peripherally or centrally administered at different doses. Results: Peripheral subchronic (24 h) pre-treatment with naloxonazine antagonised the antinociception elicited by tonic-clonic seizures. Acute (10 min) pre-treatment, however, did not have the same effect. In addition, microinjections of naloxonazine into the central, dorsal cortical and external cortical nuclei of the inferior colliculus antagonised tonic-clonic seizure-induced antinociception. Neither acute (10-min) peripheral pre-treatment with naloxonazine nor subchronic intramesencephalic blockade of mu(1)-opioid receptors resulted in consistent statistically significant differences in the severity of tonic-clonic seizures shown by Racine's index (1972), although the intracollicular specific antagonism of mu(1)-opioid receptor decreased the duration of seizures. Conclusion: mu(1)-Opioid receptors and the inferior colliculus have been implicated in several endogenous opioid peptide-mediated responses such as antinociception and convulsion. The present findings suggest the involvement of mu(1)-opiate receptors of central and pericentral nuclei of the inferior colliculus in the modulation of tonic-clonic seizures and in the organisation of post-ictal antinociception. (C) 2011 Elsevier Ltd. All rights reserved.

mu(1)- and 5-HT1-dependent mechanisms in the anterior pretectal nucleus mediate the antinociceptive effects of retrosplenial cortex stimulation in rats

Aim: This study examines if injection of cobalt chloride (CoCl2) or antagonists of muscarinic cholinergic (atropine), mu(1)-opioid (naloxonazine) or 5-HT1 serotonergic (methiothepin) receptors into the dorsal or ventral portions of the anterior pretectal nucleus (APtN) alters the antinociceptive effects of stimulating the retrosplenial cortex (RSC) in rats. Main method: Changes in the nociceptive threshold were evaluated using the tail flick or incision pain tests in rats that were electrically stimulated at the RSC after the injection of saline, CoCl2 (1 mM, 0.10 mu L) or antagonists into the dorsal or ventral APtN. Key findings: The injection of CoCl2, naloxonazine (5 mu g/0.10 mu L) or methiothepin (3 mu g/0.10 mu L) into the dorsal APtN reduced the stimulation-produced antinociception from the RSC in the rat tail flick test. Reduction of incision pain was observed following stimulation of the RSC after the injection of the same substances into the ventral APtN. The injection of atropine (10 ng/0.10 mu L) or ketanserine (5 mu g/0.10 mu L) into the dorsal or ventral APtN was ineffective against the antinociception resulting from RSC stimulation. Significance: mu(1)-opioid- and 5-HT1-expressing neurons and cell processes in dorsal and ventral APtN are both implicated in the mediation of stimulation-produced antinociception from the RSC in the rat tail flick and incision pain tests, respectively. (c) 2012 Elsevier Inc. All rights reserved.

Amitriptyline prolongs the antihyperalgesic effect of 2- or 100-Hz electro-acupuncture in a rat model of post-incision pain

The mechanisms through which electro-acupuncture (EA) and tricyclic antidepressants produce analgesia seem to be complementary: EA inhibits the transmission of noxious messages by activating supraspinal serotonergic and noradrenergic neurons that project to the spinal cord, whereas tricyclic antidepressants affect pain transmission by inhibiting the reuptake of norepinephrine and serotonin at the spinal level. This study utilized the tail-flick test and a model of post-incision pain to compare the antihyperalgesic effects of EA at frequencies of 2 or 100 Hz in rats treated with intraperitoneal or intrathecal amitriptyline (a tricyclic antidepressant). A gradual increase in the tail-flick latency (TFL) occurred during a 20-min period of EA. A strong and long-lasting reduction in post-incision hyperalgesia was observed after stimulation; the effect after 2 Hz lasting longer than after 100-Hz EA. Intraperitoneal or intrathecal amitriptyline potentiated the increase in TFL in the early moments of 2- or 100-Hz EA, and the intensity of the antihyperalgesic effect of 100-Hz EA in both the incised and non-incised paw. In contrast, it did not significantly change the intensity of the antihyperalgesic effect of 2-Hz EA. The EA-induced antihyperalgesic effects lasted longer after intraperitoneal or intrathecal amitriptyline than after saline, with this effect of amitriptyline being more evident after 100-than after 2-Hz EA. The synergetic effect of amitriptyline and EA against post-incision pain shown here may therefore represent an alternative for prolonging the efficacy of EA in the management of post-surgical clinical pain.

The antinociceptive effect of electroacupuncture at different depths of acupoints and under the needling surface

Background The stimulation of acupoints along the meridians, but not the non-acupoints outside of the meridians, produces analgesia. Although the acupoint is defined at the body surface, the exact location of the acupoints is not known. This study aims to examine whether the intensity and duration of the analgesic effect of electroacupuncture (EA) at the Zusanli (ST36) and Sanynjiao acupoints (SP6) change according to the depth of the stimulation. Methods Ninety-six male Wistar rats classified as responders were arbitrarily allocated into 16 groups of six rats each. Six groups received EA with uninsulated acupuncture needles (type I) or needles that were immersed in varnish and had the varnish circularly peeled 0.2 mm from the tip (type II), 0.2 mm at 3 mm (type III) or 5 mm (type IV) from the tip, or 0.2 mm at 5 and 1 mm from the tip (type V), or EA sham for 20 min. Five groups received injection of formalin into the acupoint bilaterally at 5 mm or 1 mm deep into ST36, 5 mm below ST36 but inserting the needle at 45° to the skin surface, or 5 mm deep into non-acupoints. The remaining groups received intraplantar injection of saline, 1% or 2.5% formalin. The analgesic effects were measured by the rat tail-flick test. Results The bilateral stimulation of ST36 and SP6 by uninsulated or insulated needles produced analgesia in the rat tail-flick test. The stronger and longer lasting effects occurred after EA with the types I and V needles, or injection of formalin 5 mm deep into ST36. The remaining needles produced weaker and shorter lasting effects. Slow analgesic effect also occurred after formalin injection at 1 mm or 5 mm below ST36 by inserting the needle at 45° to the skin surface. Conclusion The experimental results suggest that the efficacy of the EA stimulation depends on the spatial distribution of the current density under the needling surface rather than only the acupoint or the depth of needling.

Factors identifying pigs predisposed to tail biting

Approximately 5% of pigs slaughtered in the UK have been tail-bitten, leading to welfare and production issues. Tail biting is sporadic and not all pigs tail bite. The aim of this study was to identify factors that are common in pigs that perform tail-biting behaviour, and that might be used in a predictive way to identify such animals.

The behaviour of 159 pigs was observed in the post-weaning period. Pigs were weaned at 4 weeks of age. In the week prior to weaning and at 6 weeks of age each pig was individually tested in a tail chew test (tail chew test 1 and 2, respectively). The tail chew test involved recording the pig's behaviour directed towards two ropes, one of which had been soaked in saline solution and the other not. The production performance of the pigs was recorded from birth to 7 weeks of age. Time spent performing tail-biting behaviour correlated positively with time in contact with the rope in tail chew test 2 (r = 0.224, P 1.5% tail biting 8.96 kg, = 1.5% tail biting 15-75 kg, = or = 1.5% tail biting 260 g/day, = 1.5% tail biting 343 g/day, 0.05).

The results suggest that pigs that tail bite have some nutritional deficiency that results in performance of foraging behaviour that is expressed in intensive housing as ear/tail biting.

Comparative study of the sedative and antinociceptive effects of levomepromazine, azaperone and midazolam in laboratory animals

Os efeitos sedativos e antinociceptivos da levomepromazina, azaperone e midazolam foram avaliados utilizando-se três testes de comportamento em ratos e camundongos. No teste da atividade locomotora espontânea em campo aberto observou-se que tanto o comportamento exploratório como a atividade locomotora espontânea foram significativamente diminuídos quando se utilizou levomepromazina e azaperone. O efeito causado pelo azaperone foi menos prolongado quando comparado ao da levomepromazina. O midazolam causou diminuição do comportamento exploratório sem alterar a atividade locomotora espontânea. Quando se avaliou o efeito antinociceptivo por meio da latência para o reflexo da retirada da cauda em ratos após estímulo doloroso, as drogas não apresentaram nenhum efeito antinociceptivo observável. No teste das contorções em camundongos, os fármacos foram capazes de abolir as contorções quando comparados ao efeito do grupo-controle. Levomepromazina, azaperone e midazolam nas doses utilizadas foram capazes de inibir o comportamento exploratório de ratos, comprovando seus efeitos sedativos. Com relação aos efeitos antinociceptivos para dor visceral, eles foram capazes de inibir as contorções.

Antiulcerogenic and analgesic effects of the Austroplenckia populnea extracts in mice

Austroplenckia populnea (Reiss.) Lund. is a Brazilian Cerrado plant belonging to the Celastraceae family. Hexane and methanol extracts of leaves were investigated for their antiulcerogenic (ethanol and indomethacin/bethanecol induced gastric damage) and analgesic (writhing and tail-flick tests) activities in mice. Acute toxic effects also were evaluated. Oral administration of both extracts at a dose of 1000 mg/kg significantly reduced the total area of the lesion, the relative area of lesion and the ulcerative index in ethanol-induced gastric damage, but both extracts were inactive in the indomethacin/bethanecol-induced gastric damage test. A dose dependent effect was determined with the hexane extract in the ethanol-induced lesions test. The hexane and methanol extracts reduced the number of contortions in the writhing test, but both extracts were inactive in the tail-flick immersion test. Copyright (C) 2002 John Wiley Sons, Ltd.

Antiulcerogenic and analgesic effects of Maytenus aquifolium, Sorocea bomplandii and Zolernia ilicifolia

Maytenus aquifolium (Celastraceae), Sorocea bomplandii (Moraceae) and Zolernia ilicifolia (Fabaceae) are native plants from the Tropical Atlantic Forest (Mata Atlantica, Brazil) known a 'espinheira-santa'. These plants are traditionally used as analgesic and antiulcerogenic medicine, with the same traditional uses of the true 'espinheira-santa' (Maytenus ilicifolia, Celastraceae), an efficient antiulcerogenic agent. Pharmacological and toxicological studies with these plants have not been carried out. The purpose in this study was to evaluate the efficacy (analgesic and antiulcerogenic activities), safety (acute toxicity) and quality (phytochemical profile) of these three plants. The analgesic effect was analyzed by writhing and tail flick tests, while anti Ulcerogenic effect was performed through ulcer induction by ethanol and indomethacin/bethanecol assays. LD., and acute toxic effects, as well as phytochemical profiles of all plants also were carried. Surprisingly, the three plants showed analgesic and antiulcerogenic effects at dose of 1000 mg/kg, v.o. Maytenus aquifolium lowering all ulcerogenic parameters (ethanol test), but increased the ulcerogenic effects in the indoniethacin/bethanecol test. Sorocea bomplandii produced antiulcerogenic effects in both experimental models used, while Zolernia ilicifolia showed significant effects only in indomethacin/bethanecol-induced gastric lesions. Pre-treatment with Zolernia ilicifolia induced someone toxic effects, A phytochemical profile for each plant species was determined and its main chemical classes of compounds were described. (C) 2001 Elsevier B.V. Ireland Ltd. All rights reserved.

Applications of the hexanic fraction of Agave sisalana Perrine ex Engelm (Asparagaceae): control of inflammation and pain screening

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Indagine sul coinvolgimento del sistema neuropeptidergico nocicettina/recettore NOP a carico della trasmissione nocicettiva

Oggetto di studio in questa tesi è stato il ruolo modulatorio svolto dal neuropeptide nocicettina/orfanina FQ a carico della trasmissione nocicettiva. A scopo introduttivo, sono state illustrate le conoscenze attuali sul sistema nocicettina-NOP; sono state descritte le funzioni, la struttura e la distribuzione del recettore NOP, le azioni farmacologiche finora note e la distribuzione della nocicettina stessa al livello del S.N.C. e in periferia. Lo studio è stato condotto principalmente con due approcci differenti A) E’ stata studiata la capacità della nocicettina esogena o di suoi analoghi agonisti e antagonisti, di modificare la trasmissione nocicettiva. B) Sono state studiate le variazioni a carico del sistema endogeno nocicettina/recettore NOP in seguito a trattamenti di tipo farmacologico. A) E’ stata indagata la capacità della nocicettina e degli analoghi sintetici [Arg14, Lys15]N/OFQ e UFP-101 di modificare la soglia nocicettiva nel ratto, rilevata con il test del tail-flick, a seguito di somministrazione diretta nello spazio subaracnoideo, in confronto con la nocicettina stessa. La somministrazione intratecale del neuropeptide nocicettina (10 nmol/ratto) ha determinato un innalzamento statisticamente significativo delle latenze di risposta al test del tail-flick. L’analogo [Arg14, Lys15]N/OFQ è stato somministrato alla dose di 1 nmole/ratto i.t. provocando un innalzamento massimale delle soglie di latenza per tutto il periodo di osservazione, mentre alla dose 0,2 nmoli/ratto i.t ha provocato un effetto antinocicettivo sottomassimale pur dimostrandosi significativo rispetto ai controlli (p < 0,05 vs controlli a tutti i tempi di rilevazione). Il composto antagonista UFP-101 è risultato capace di antagonizzare l’azione sulla soglia analgesica sia della nocicettina sia dell’analogo [Arg14, Lys15]N/OFQ nel suo dosaggio minore, mentre contro la dose di 1 nmole/ratto i.t ha prodotto solamente una riduzione di effetto. Anche la somministrazione intratecale di MAP-N/OFQ si è dimostrata in grado di modificare la soglia nocicettiva determinata mediante il test del tail-flick, nel ratto, in modo dose dipendente. differentementeuna seconda somministrazione di MAP-N/OFQ dopo 24 ore, si è dimostrata totalmente inefficace nel modificare la soglia nocicettiva nei ratti precedentemente trattati, pur permanendo la loro suscettibilità all’azione analgesica della morfina, mostrando quindi il rapido sviluppo di tolerance al potente peptide nocicettinergico somministrato per via i.t.. Inoltre l’antagonista UFP-101 oltre ad essere ingrado di antagonizzare l’effetto della MAP-N/OFQ, ha mostrato la capacità di ridurre la tolerance sviluppata nei confronti del dendrimero. La somministrazione di MAP-N/OFQ per via i.c.v. ha prodotto variazione della soglia nocicettiva, producendo un innalzamento del volore soglia, dato contrastante con la maggior parte dei dati riguardanti la nocicettina in letteratura. Ha invece replicato l’effetto di antagonismo funzionale nei confronti della morfina, la quale dopo somministrazione di MAP-N/OFQ è risultata essere incapace di modificare la soglia nocicettiva nel ratto. Tale effetto perdura dopo 24 ore, quando una somministrazione di morfina produce un effetto analgesico inversamente proporzionale alla dose ricevuta di MAP-N/OFQ 24 ore prima. E’stato indagato il possibile ruolo neuromodulatorio del neuropeptide nocicettina esogeno, nell’analgesia prodotta da un farmaco di natura non oppiacea. In tal senso si è proceduto ad indagare l’eventuale capacità della nocicettina esogena, somministrata per via intracerebroventricolare e del suo analogo [Arg14, Lys15]N/OFQ, di antagonizzare l’analgesia prodotta dal farmaco paracetamolo. La nocicettina ha evidenziato la capacità di antagonizzare il potere antinocicettivo del paracetamolo fino a bloccarne completamente l’effetto al dosaggio più elevato, mostrando quindi proprietà antagonista dose-dipendente. Inoltre l’UFP-101, che di per se non altera l’analgesia indotta da paracetamolo, è ingrado di antagonizzare l’effetto della nocicettina sul paracetamolo in maniera dose-dipendente. Medesimo è risultato il comportamento dell’analogo della nocicettina, la Arg-Lys nocicettina. B) Sono state indagate le relazioni tra il sistema nocicettina/NOP e le proprietà farmacologiche di un noto farmaco oppiaceo quale la buprenorfina, le cui peculiari caratteristiche farmacodinamiche sano state recentemente collegate alla sua capacità di agire come agonista diretto al recettore NOP. In tal senso si è proceduto ad osservare l’effetto della somministrazione di buprenorfina sull’ assetto recettoriale di NOP, inseguito ad un trattamento prolungato con somministrazione sottocutanea mediante minipompe osmotiche nel ratto, rilevando successivamente, tramite uno studio di binding, le variazioni della densità recettoriale di NOP in alcune aree di interesse per la trasmissione nocicettiva. Sia nell’ippocampo che nel talamo e nella frontal cortex, la somministrazione prolungata di buprenorfina ha causato una riduzione significativa della densità recettoriale di NOP. Come ultimo aspetto indagato, al fine di determinare la presenza del neuropeptide nel liquido cerebrospinale e le sue eventuali modificazioni a seguito di manipolazioni farmacologiche e non farmacologiche, è stata messa a punto una metodica di perfusione dello spazio subaracnoideo nel ratto, che consentisse di ottenere materiale biologico su cui compiere la ricerca e quantificazione della presenza di nocicettina mediante dosaggio radioimmunologico. La perfusione di CSF artificiale arricchito di ione potassio ad una concentrazione pari a 60 mM ha evidenziato la possibilità di stimolare la liberazione della nocicettina nel liquido cerebrospinale di ratto, suggerendo quindi una sua provenienza da elementi eccitabili. E’ stato quindi possibile osservare l’andamento dei livelli di peptide a seguito della stimolazione nocicettiva prodotta da due agenti irritanti con caratteristiche differenti, la carragenina e la formalina. La somministrazione sottocutanea di carragenina (100 µl al 3 %) nella regione subplantare di entrambe le zampe posteriori del ratto non ha determinato alterazioni significative dei livelli di neuropeptide. Invece, la somministrazione di formalina (50 µl al 5 %), dopo un iniziale periodo di 30 minuti, ha causato un incremento significativo della liberazione di N/OFQ a partire dal terzo intervallo di raccolta seguente la somministrazione della sostanza. Questo rispecchia l’andamento di risposta al formalin test ottenuto anche mediante test di natura differente dagli analgesimetrici (es. comportamentale, elettrofisiologico), in quest’ottica l’aumento di nocicettina può essere interpretato come un evento dovuto alla sensibilizzazione centrale all’effetto pronocicettivo.

The analysis and detection of new psychoactive substances in biological matrices

New psychoactive substances (NPSs) have appeared on the recreational drug market at an unprecedented rate in recent years. Many are not new drugs but failed products of the pharmaceutical industry. The speed and variety of drugs entering the market poses a new complex challenge for the forensic toxicology community. The detection of these substances in biological matrices can be difficult as the exact compounds of interest may not be known. Many NPS are sold under the same brand name and therefore users themselves may not know what substances they have ingested. The majority of analytical methods for the detection of NPSs tend to focus on a specific class of compounds rather than a wide variety. In response to this, a robust and sensitive method was developed for the analysis of various NPS by solid phase extraction (SPE) with gas chromatography mass spectrometry (GCMS). Sample preparation and derivatisation were optimised testing a range of SPE cartridges and derivatising agents, as well as derivatisation incubation time and temperature. The final gas chromatography mass spectrometry method was validated in accordance with SWGTOX 2013 guidelines over a wide concentration range for both blood and urine for 23 and 25 analytes respectively. This included the validation of 8 NBOMe compounds in blood and 10 NBOMe compounds in urine. This GC-MS method was then applied to 8 authentic samples with concentrations compared to those originally identified by NMS laboratories. The rapid influx of NPSs has resulted in the re-analysis of samples and thus, the stability of these substances is crucial information. The stability of mephedrone was investigated, examining the effect that storage temperatures and preservatives had on analyte stability daily for 1 week and then weekly for 10 weeks. Several laboratories identified NPSs use through the cross-reactivity of these substances with existing screening protocols such as ELISA. The application of Immunalysis ketamine, methamphetamine and amphetamine ELISA kits for the detection of NPS was evaluated. The aim of this work was to determine if any cross-reactivity from NPS substances was observed, and to determine whether these existing kits would identify NPS use within biological samples. The cross- reactivity of methoxetamine, 3-MeO-PCE and 3-MeO-PCP for different commercially point of care test (POCT) was also assessed for urine. One of the newest groups of compounds to appear on the NPS market is the NBOMe series. These drugs pose a serious threat to public health due to their high potency, with fatalities already reported in the literature. These compounds are falsely marketed as LSD which increases the chance of adverse effects due to the potency differences between these 2 substances. A liquid chromatography tandem mass spectrometry (LC-MS/MS) method was validated in accordance with SWGTOX 2013 guidelines for the detection for 25B, 25C and 25I-NBOMe in urine and hair. Long-Evans rats were administered 25B-, 25C- and 25I-NBOMe at doses ranging from 30-300 µg/kg over a period of 10 days. Tail flick tests were then carried out on the rats in order to determine whether any analgesic effects were observed as a result of dosing. Rats were also shaved prior to their first dose and reshaved after the 10-day period. Hair was separated by colour (black and white) and analysed using the validated LC-MS/MS method, assessing the impact hair colour has on the incorporation of these drugs. Urine was collected from the rats, analysed using the validated LC-MS/MS method and screened for potential metabolites using both LC-MS/MS and quadrupole time of flight (QToF) instrumentation.

Internal and external motivation factors in virtual and collocated project environments : a principal component investigation

In this study, we explore motivation in collocated and virtual project teams. The literature on motivation in a project set.,ting reveals that motivation is closely linked to team performance. Based on this literature, we propose a set., of variables related to the three dimensions of ‘Nature of work’, ‘Rewards’, and ‘Communication’. Thirteen original variables in a sample size of 66 collocated and 66 virtual respondents are investigated using one tail t test and principal component analysis. We find that there are minimal differences between the two groups with respect to the above mentioned three dimensions. (p= .06; t=1.71). Further, a principal component analysis of the combined sample of collocated and virtual project environments reveals two factors- ‘Internal Motivating Factor’ related to work and work environment, and ‘External Motivating Factor’ related to the financial and non-financial rewards that explain 59.8% of the variance and comprehensively characterize motivation in collocated and virtual project environments. A ‘sense check’ of our interpretation of the results shows conformity with the theory and existing practice of project organization

Role of G protein coupled inwardly rectifier K+ channels (GIRK) on the neurobiology depression

353 págs.

Hemisferectomia unilateral na vida adulta como modelo para o estudo das assimetrias motoras em camundongos

Em humanos, uma série de estudos vem sugerindo que o hemisfério esquerdo é particularmente importante no controle e execução de movimentos. De modo geral, lesões no hemisfério esquerdo promovem déficits motores mais pronunciados que lesões semelhantes no hemisfério direito. Neste trabalho utilizamos a hemisferectomia unilateral para avaliar a contribuição de cada hemisfério na função motora em camundongos. Camundongos Suíços adultos foram submetidos a hemisferectomia unilateral direita (HD) ou esquerda (HE) ou aos procedimentos de controle. Quinze dias após cirurgia, a coordenação motora de cada animal foi avaliada no teste da locomoção forçada em cilindro giratório (Rotarod). A latência para a queda do grupo controle foi significativamente maior que a do grupo HD e não diferiu da do grupo HE. Para auxiliar a interpretação dos resultados obtidos no ROTAROD, uma parte dos animais foi submetida a uma bateria adicional de testes comportamentais na seguinte seqüência: teste de campo aberto, avaliação qualitativa da assimetria sensório-motora, teste da grade elevada e teste de suspensão pela cauda. De modo interessante, no teste da grade elevada, enquanto o grupo HD apresentou o desempenho da pata traseira esquerda (contralateral à lesão) significativamente pior que o da direita, os grupos Controle e HE não apresentaram diferenças entre as duas patas traseiras. De modo análogo ao observado em humanos, nossos resultados sugerem uma ação assimétrica dos hemisférios cerebrais no controle da função motora em camundongos.

P-glycoprotein inhibition as a strategy to increase drug delivery across the blood-brain barrier: focus on antidepressants

Depression is among the leading causes of disability worldwide. Currently available antidepressant drugs have unsatisfactory efficacy, with up to 60% of depressed patients failing to respond adequately to treatment. Emerging evidence has highlighted a potential role for the efflux transporter P-glycoprotein (P-gp), expressed at the blood-brain barrier (BBB), in the aetiology of treatment-resistant depression. In this thesis, the potential of P-gp inhibition as a strategy to enhance the brain distribution and pharmacodynamic effects of antidepressant drugs was investigated. Pharmacokinetic studies demonstrated that administration of the P-gp inhibitors verapamil or cyclosporin A (CsA) enhanced the BBB transport of the antidepressants imipramine and escitalopram in vivo. Furthermore, both imipramine and escitalopram were identified as transported substrates of human P-gp in vitro. Contrastingly, human P-gp exerted no effect on the transport of four other antidepressants (amitriptyline, duloxetine, fluoxetine and mirtazapine) in vitro. Pharmacodynamic studies revealed that pre-treatment with verapamil augmented the behavioural effects of escitalopram in the tail suspension test (TST) of antidepressant-like activity in mice. Moreover, pre-treatment with CsA exacerbated the behavioural manifestation of an escitalopram-induced mouse model of serotonin syndrome, a serious adverse reaction associated with serotonergic drugs. This finding highlights the potential for unwanted side-effects which may occur due to increasing brain levels of antidepressants by P-gp inhibition, although further studies are needed to fully elucidate the mechanism(s) at play. Taken together, the research outlined in this thesis indicates that P-gp may restrict brain concentrations of escitalopram and imipramine in patients. Moreover, we show that increasing the brain distribution of an antidepressant by P-gp inhibition can result in an augmentation of antidepressant-like activity in vivo. These findings raise the possibility that P-gp inhibition may represent a potentially beneficial strategy to augment antidepressant treatment in clinical practice. Further studies are now warranted to evaluate the safety and efficacy of this approach.